$1.9 Billion Biopharmaceuticals Manufacturing Consumables Testing Market Report, 2034: Global and Regional Data Projections by Type, Raw Material, Application, and End-user
13 juin 2024 05h16 HE
|
Research and Markets
Dublin, June 13, 2024 (GLOBE NEWSWIRE) -- The "Global Biopharmaceuticals Manufacturing Consumables Testing Market" report has been added to ResearchAndMarkets.com's offering.The global...
Global Monoclonal Antibodies Market Report 2024-2032, by Production Method, Source, Indication, End Use and Region
12 juin 2024 11h25 HE
|
Research and Markets
Dublin, June 12, 2024 (GLOBE NEWSWIRE) -- The "Global Monoclonal Antibodies Market Report by Production Method, Source, Indication, End Use, and Region 2024-2032" report has been added to ...
Trispecific Antibodies Set to Transform the Future of Immunotherapy: Trispecific Antibodies Clinical Trials Insight by Company, Country, Indication & Phase
07 juin 2024 02h59 HE
|
Research and Markets
Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Global Trispecific Antibodies Clinical Trials & Market Outlook 2024" report has been added to ResearchAndMarkets.com's offering. The blueprint...
Global Tetraspecific Antibodies Clinical Trials & Market Report 2024: Pioneering the Future of Cancer Treatment, Shift Towards Tetraspecific Antibodies Amidst Drug Resistance Challenges
31 mai 2024 04h48 HE
|
Research and Markets
Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Global Tetraspecific Antibodies Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's...
Dyadic to Attend Industry Events in June
30 mai 2024 16h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of...
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
28 mai 2024 07h35 HE
|
Numab Therapeutics AG
Numab Therapeutics Announces J&J to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for AD
Fc and Glycoengineered Antibodies Research 2024: Market Experiences Over 30% Growth in Collaborations in Past Two Years, Fueled by Strategic Partnerships - Long-term Forecasts to 2035
22 mai 2024 04h47 HE
|
Research and Markets
Dublin, May 22, 2024 (GLOBE NEWSWIRE) -- The "Fc and Glycoengineered Antibodies Market: Industry Trends and Global Forecasts, till 2035: Distribution by Type of Engineering, Type of Therapy,...
BioNTech präsentiert auf der ASCO-Jahrestagung 2024 klinische Daten-Updates zu innovativen Immuntherapie-Kandidaten
21 mai 2024 06h45 HE
|
BioNTech SE
MAINZ, Deutschland, 21. Mai 2024 – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf der diesjährigen Jahrestagung der American Society of Clinical Oncology („ASCO“), die vom 31....
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
21 mai 2024 06h45 HE
|
BioNTech SE
MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company’s diversified immuno-oncology pipeline at...
Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
14 mai 2024 16h00 HE
|
Dyadic International, Inc.
Human Health Sector Final Clinical Study Report has been issued for the First-In-Human Phase 1 clinical trial demonstrating safety and antibody response for DYAI-100, a recombinant...